.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists recently reported promising results for Biologic Ventricular Assist Tissue (BioVAT) in the New England Journal of Medicine. Therefore, this technology represents a significant step forward in regenerative medicine for cardiac repair. In this open-label trial, clinicians treated patients with heart failure using allografts of engineered heart muscle. Moreover, the trial specifically targeted individuals with a reduced left ventricular ejection fraction (LVEF) of 35% or less. Consequently, the researchers observed meaningful improvements in both heart structure and patient symptoms.
The study highlights how BioVAT effectively remuscularizes damaged cardiac tissue. For instance, the target heart-wall thickness increased by an average of 4.5 mm after transplantation. Furthermore, the patients\' quality of life improved considerably, showing a 15.3-point increase in KCCQ-OSS scores. Although three patients died during the study, the investigators found no deaths directly related to the surgical procedure itself. Because of these findings, BioVAT may eventually offer a viable alternative to mechanical assist devices. Nevertheless, long-term safety data remains essential before widespread clinical adoption in India.
Additionally, the trial demonstrated a mean increase in LVEF of 4.7 percentage points among the treated group. This improvement suggests that the stem-cell-derived cardiomyocytes successfully integrated into the host heart. In fact, most patients who completed the follow-up showed sustainable results at the three-month mark. Thus, the safe maximal dose of 20 engineered-heart-muscle units appears both feasible and effective for terminal heart failure patients.
BioVAT is a tissue-engineered product composed of cardiomyocytes and stromal cells derived from induced pluripotent stem cells. It acts as a biological patch to repair and strengthen the failing heart.
It increases the thickness of the heart wall and improves the heart\'s pumping ability. Consequently, patients experience better physical function and fewer symptoms of heart failure.
Currently, BioVAT remains in the clinical trial phase. While results are promising, it is not yet available for routine clinical use outside of research settings.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Zimmermann WH et al. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. N Engl J Med. 2026 May 28. doi: 10.1056/NEJMoa2513525. PMID: 42202318.
ClinicalTrials.gov. BioVAT-HF: Safety and Efficacy of iPSC-derived Engineered Human Myocardium. NCT04396899.
FirstWord Pharma. BioVAT-HF Phase 1/2 Reveals First Evidence for Effective Heart Repair in Advanced Heart Failure. 2023 Nov 14.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A phase 1-2 study in NEJM shows BioVAT transplantation significantly increases heart wall thickness and ejection fraction in advanced heart failure patients...
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
